Kornimate/medical-research-clean huggingface dataset:
a study of nivolumab and ipilimumab combined with chemotherapy compared to chemotherapy alone in first line nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to determine whether nivolumab, ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage iv nsclc as the first treatment given for the disease


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * participants with histologically confirmed stage iv or recurrent nsclc squamous or non-squamous histology, with no prior systemic anticancer therapy * eastern cooperative oncology group (ecog) performance status of ≤ 1 * measurable disease by ct or mri per response evaluation criteria in solid tumors version 1.1 (recist 1.1) criteria * participants must have pd-l1 ihc testing with results performed by a central laboratory during the screening period exclusion criteria: * participants with known epidermal growth factor receptor (egfr) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 \[l858r\] substitution mutations) are excluded * participants with known anaplastic lymphoma kinase (alk) translocations which are sensitive to available targeted inhibitor therapy are excluded * participants with untreated cns metastases are excluded. participants are eligible if cns metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the cns treatment) for at least 2 weeks prior to first treatment other protocol inclusion/exclusion criteria may apply
assessment of unilateral lymphoedema of the leg

Conditions: Lymphedema

Summary: to demonstrate that impedimed l-dex u400 can be used to assess unilateral lymphoedema of the leg using the same principles for arms.

when lymphoedema is present, lymph and other fluids build up in the interstitial spaces of the tissues. this results in an overall increase in the total amount of extracellular fluid (ecf) in the limb, causing swelling. this can be documented by measuring the impedance (opposition) to a low frequency current that has been passed into the limb. low frequency current travels predominantly through the ecf, where the lymphoedema manifests. as the fluid builds up in the limb, the impedance to the current decreases and it is in this way that low frequency bioimpedance is able to assess lymphoedema. multi-frequency bio-impedance analysis otherwise known as bioimpedance spectroscopy (bis) has been reported to be effective for the measurement of ecf and sub clinical changes in ecf to predict the onset of lymphoedema in the arms in studies conducted by cornish et al. it has been reported by warren et al that bis can be used as a reliable and accurate tool for documenting presence of lymphoedema in patients with wither upper- or lower-extremity swelling. the l-dex u400 device uses an "impedance ratio" methodology to assess unilateral lymphoedema of the arm. by this method the unaffected arm acts as an internal and subject specific control. the strategy of this study is to show that the l-dex u400 can use this methodology to assess unilateral leg lymphoedema.

Eligibility criteria:
inclusion criteria: group 1: * be between the ages of 18-75 years. * self-describe general health as satisfactory. * understand the proposed study and be willing and fully able to comply with the study procedures. * be a willing participant and be capable of giving and has given informed written consent for entry into the study. * have been previously diagnosed, by current clinical practice, as having unilateral lymphoedema of the leg. group 2: * be between the ages of 18-75 years. * self-describe general health as satisfactory. * understand the proposed study and be willing and fully able to comply with the study procedures. * be a willing participant and be capable of giving and has given informed written consent for entry into the study. exclusion criteria: * have a known heart condition or an implantable device such as a pacemaker or icd. * have a metallic surgical implant (e.g. total hip replacement) not including small implants such as sternal wires or surgical staples. * suffer from a renal disorder. * be taking diuretic medications. * have consumed large amounts of alcohol or caffeinated beverages within six hours of the study. * have undertaken excessive exercise within two hours of bia * have a reported fever of \> 38°c at time of screening. * be currently in the fourth week of the menstrual cycle. * be pregnant or currently breastfeeding.

Keywords: lymphedema bioimpedance
primary care referrals to community-based lifestyle programs for management of obesity

Conditions: Obesity; Lifestyle, Healthy; Community Based Programs; Primary Care Referrals

Summary: the purposes of this study is to evaluate the feasibility of providing a community based referral to mayo clinic employee and community health patients for weight loss.


Eligibility criteria:
inclusion criteria: * patients who are between 18-65 years of age * patients who have a bmi between 25-39.9 kg/m2 * ability to provide informed consent * ability to complete the diabetes prevention program including dietary and physical activity recommendations * motivated to lose weight (assessed to be in the preparation or action stage) exclusion criteria: * have used weight loss medications or participated in a weight loss program within the past 30 days. * are currently enrolled in dpp or other exercisabilities weight loss programs * are currently taking supplements known to affect weight. * have had weight fluctuations of 20 pounds or more in the past 6 months (emr check and self-report) * have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression) * are currently pregnant or breastfeeding, or are of child-bearing potential and are likely to become pregnant during the study (within the next 4 months following enrollment) * have a history in the past 4 months of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease * have current uncontrolled hypertension (systolic \> 160 mm hg or diastolic \> 95 mm hg) documented on 2 separate occasions * have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission * have a known history of any condition or factor judged by the investigator/study team to preclude participation in the study or which might hinder adherence * have any co-morbidity that is deemed exclusionary at the discretion of the provider.
erector spinae block and transverse abdominis plane block for sleeve gasterectomy

Conditions: Bariatric Surgery Candidate

Summary: assess the efficacy of ultrasound guided erector spinae block to decrease the requirement for analgesics after laparoscopic sleeve gastrectomy and to decrease postoperative pain scores and opioid consumption compared to subcostal transverses abdominis block.

primary outcomes • cumulative opioid consumption during the first 24 h postoperatively. for the purpose of comparison, all opioids administered postoperatively will be converted to iv morphine equivalent doses using standard opioid dosage conversion tables. secondary outcome parameters 1. pain assessment by the aid of visual analogue scale (vas), which is consisted of a "10 cm" line with one end labeled no pain and other end labeled worst intolerable pain. the patients marked the line at the point that best describing the pain intensity. the preoperative assessment included training of the patients about (vas) for postoperative pain. the length of the line to the patient's mark will be measured and recorded postoperative after 30 min., 4, 6, 8, and 24 hours. 2. failure rate of the block will be calculated, where the block will be considered a failed block if the patient requires more than two doses of rescue analgesia in the first hour postoperatively. 3. duration of surgery (from skin incision till skin closure) and general anesthesia (from induction of ga till extubation). 4. incidence of complications, such as: nerve injury, hematoma formation, la toxicity, and intravascular injection.

Eligibility criteria:
inclusion criteria: * • patients from 18 to 59 years. * bmi \> 40 kg/m2 * genders eligible for study: both. * asa i-iii. * no contraindications for application of regional anesthesia as patient refusal, local anesthetic allergy, local sepsis or infection at puncture site, inr \> 1.5 or \< 12 hours post lmwh. exclusion criteria: * • patient refusal. * extremes of age. * asa iv. * increased intracranial pressure. * coagulopathy or thrombocytopenia less than 100000/ml. * sepsis (increased risk of meningitis). * infection at the puncture site. * pre-existing neurologic disease. * history of allergy to local anesthetic.
an internet-based behavioral weight loss program for hiv+ patients

Conditions: Overweight; Obesity; HIV

Summary: the goal of this project is to determine whether an internet-based weight loss program will lead to weight loss and improvements in cardiovascular disease risk factors in people living with hiv.

the goal of this project is to provide an empirically validated weight loss program to hiv+ patients and evaluate its efficacy for weight loss and improvements in cardiovascular disease risk factors. investigators will conduct a randomized pilot study with 50 overweight or obese patients who are hiv+, are recruited from the miriam hospital immunology center, and are interested in losing weight. these patients will be randomly assigned to a 12 week behavioral weight loss program delivered via the internet or to a 12 week education only control group (also internet based). primary aims of this study are 1) to determine whether an internet program is appropriate for this patient population, assessed by the success of recruiting 50 patients for the trial and their level of adherence over the 12 weeks, 2) to compare weight losses at the end of the 12 week program for program for patients randomized to the internet behavioral weight reduction program (wt loss) relative to the internet education program (control), 3) to compare the efficacy of the wt loss program relative to control for improving lipids (total cholesterol, hdl, ldl, triglycerides), metabolic measures (fasting blood sugar, insulin), and inflammatory markers (il-6, c-reactive protein, adiponectin), and 4) to compare the changes in dietary intake and physical activity from baseline to 12 weeks in the wt loss and control conditions. investigators will also store blood for later analysis of other adipokines (leptin) and biomarkers of microbial gut translocation (e.g., scd14). these will provide important pilot data for future nih funding related to both the implementation of weight loss programs and the effect of weight loss on the co-morbidities in this population.

Eligibility criteria:
inclusion criteria: * recruited from the miriam hospital immunology center * hiv+ with a cd4 count \>200 and an undetectable viral load * bmi greater than 27 kg/m2 * no health problems that make weight loss or unsupervised exercise unsafe * english speaking * have access to a computer and the internet exclusion criteria: * report a heart condition, chest pain during periods of activity or rest, or loss of consciousness on the physical activity readiness questionnaire * active substance abuser * currently pregnant or intend to become pregnant in the next 6 months * planning to move outside of the state within the next 6 months * have participated in a study conducted by the weight control \& diabetes research center in the past 2 years
the value of combined detection of orexin-a, hla gene, psg and mslt in the evaluation of patients with narcolepsy

Conditions: Narcolepsy

Summary: by comparing the differences of orexin-a, hla gene, psg, mslt and other parameters in the evaluation of narcolepsy patients, investigators could find out the relatively high value indicators in the diagnosis of narcolepsy, which is helpful to guide the clinical discovery, diagnosis and treatment of narcolepsy.

narcolepsy is a lifelong sleep disorder disease, mainly occurs in the 15\~30 year old youth. the incidence rate in different country population is different, which is 0.04% in china. because of its low incidence rate, and the lack of clinicians' knowledge, it is easy to cause missed diagnosis and misdiagnosis. the decrease of cerebrospinal fluid orexin-a level, positive hla-dqb1 \* 0602 and mslt all have directive significance for the diagnosis of narcolepsy, but patients with other diseases and healthy people can also show positive indicators. these false positives may lead to wrong judgments. by comparing the differences of orexin-a, hla gene, psg, mslt and other parameters in the evaluation of narcolepsy patients, investigators could find out the relatively high value indicators in the diagnosis of narcolepsy, which is helpful to guide the clinical discovery, diagnosis and treatment of narcolepsy.

Eligibility criteria:
inclusion criteria: 1. patients aged 10-70 years old; 2. the symptoms lasted for at least 3 months; 3. with or without cataclysm; 4. mslt showed that the sleep latency was less than or equal to 8 min, there were two or more times of sleep, the onset of rem sleep; 5. somnolence can not be explained by other diseases, such as insufficient sleep, osahs, delayed sleep phase, drug or drug use, etc. exclusion criteria: 1. somnolence was caused by sleep disorders, central nervous system diseases, brain trauma and other non narcolepsy; 2. recent lack of sleep or irregular sleep; 3. psg and mslt examination can not be diagnosed as narcolepsy; 4. poor compliance, taking drugs or food and beverage containing central inhibitory components during the trial; 5. severe neuropsychiatric disorders can not cooperate with the examination; 6. patients with history of rheumatism, diabetes, ankylosing spondylitis and other hla related diseases.

Keywords: narcolepsy orexin hla gene polysomnography multiple sleep latency test
study to evaluate diagnostic sensitivity and specificity of istatis syphilis ab test at the point- of-care sites

Conditions: Syphilis Infection; Syphilis

Summary: this study is a prospective cross-sectional study in which surgically non-invasive sample- taking is done only for the purpose of the study. capillary (fingerstick) whole blood and plasma (i.e., obtained through venous edta whole blood collection and processing) are collected by a healthcare professional. the collected samples are tested in a routine testing environment, i.e., healthcare providers at

a trained healthcare provide will collect 50μl of capillary whole blood and 11ml of edta venous whole blood (vwb) to be tested with the istatis syphilis ab test on site according to the 'test procedure' described in the instructions for use (ifu) supplied with the reagents. same procedure must be followed using the extracted plasma sample to test 30μl of the plasma sample extracted and obtained through processing of the vwb on the istatis syphilis ab test. an aliquot of the plasma sample will be transferred to the central laboratory to establish the reference test result using an enzyme immunoassay (eia) (abbott architect syphilis tp eda). in case of positive results in the eia reference test of (abbott architect syphilis tp eda), the sample will be sent for bd macro-vue particle agglutination (rpr) and serodia particle agglutination (tppa) testing.

Eligibility criteria:
inclusion criteria: * participants/subjects (males, females, and pregnant women) getting tested for syphilis for one or more of the following reasons: o at risk for syphilis ohaving signs and symptoms indicative for syphilis oroutine testing * participants/subjects of 18 years or older and, who are able to give/sign the informed consent. exclusion criteria: * participant younger than 18 years old * participants unable to provide written informed consent * participants currently undergoing treatment

Keywords: syphilis rapid test syphilis point of care tests syphilis antibody test istatis syphilis ab test istatis syphilis antibody test
the contact activation system and ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the study aims to describe alterations in the contact activation system during active and inactive ulcerative colitis. contact activation system measures are compared in a cross sectional (healthy controls vs. active disease) and longitudinal (active diasese vs. inactive disease) fashion.

we include and follow up on 102 adults with active ulcerative colitis. visits are week 0 (inclusion), 6, 12 and 26 (end of study). we obtain plasma and fecal samples at each visit. whereas we obtain colonic tissue samples only at inclusion and end of study. registered data are: * demographics realate to uc and general wellbeing. * clinical parametres used for uc evaluation are pro2, sccai, crp, fecal calprotectin, mayo endoscopic subscore and nancy index. * the contact activation system is characterised by fxii, prekallikrein, kallikrein generation, hk, chk (specific to plasma kallikrein), chk (specific to tissue kallikrein), c1 inhibitor and kallistatin. * polymerized alpha-1-antitrypsin is characterised by the degree of polymerization and the capacity to activate the contact activation system.

Eligibility criteria:
inclusion criteria: * fulfill diagnostic criteria of ulcerative colitis * sccai score ≥ 5 * mayo endoscopic subscore ≥ 1 * age ≥ 18 years * most understand written and oral information in danish * informed consent must be given exclusion criteria: * pregnancy * infection at inclusion * any existing disease at inclusion: * liver disease or defect in cas * inflammatory rheumatologic or dermatologic disease * cardiovascular or renal disease * immunodeficiency or hematologic diseases * malignancies * medication with * systemic corticosteroids at inclusion * ace-inhibitor * acetylsalicylic acid/nsaid * warfarin, phenprocoumon, noac and heparins

Keywords: misfolded protein coagulation factor xii kallikrein high molecular weight kininogen the contact activation system endoplasmatic reticulum stress misfolded alpha-1-antitrypsin inflammatory bowel disease inflammation
study for effectiveness evaluation of panax ginseng, vitamins and minerals (natugerin®) in improvement of stress and fatigue

Conditions: Stress; Fatigue

Summary: it is hoped that the group treated with panax ginseng, vitamins and minerals obtain significant reduction in levels of stress and fatigue and that the results are superior to the placebo group.


Eligibility criteria:
inclusion criteria: * agree with all study procedures, signing the ic in two ways, by his own free will; * patients older than 18 years, male or female, regardless of ethnicity or social class; * presence of pictures of mild to moderate stress, confirmed with the aid of the stress symptom inventory (iss), which considers stress and mild to moderate classification alert classification resistance; * presence frame of fatigue with a score greater than 36 according to the fatigue severity scale (fss). exclusion criteria: * participation in clinical trials in the 12 months preceding the survey; * current treatment with drugs that are stimulants or central nervous system depressants such as hypnotics, anxiolytics, antipsychotics, antidepressants, statins and muscle relaxants; * alternative therapies that scientifically, or have no influence in the tables of stress or fatigue as acupuncture or relaxing massages; * treatment psychotherapeutic medication or not; * current treatment or prediction of treatment with oral anticoagulants (due to interaction with the tocopherol); * women who are pregnant or lactating; * patients with lactose intolerance; * patients allergic to soy or peanuts; * chronic renal failure; * patients using other multivitamins or individual vitamins such as vitamin d and / or a. * chronic alcoholism; * patients with clinical diagnosis of diseases causing severe chronic pain or adversely affect the clinical interpretation as fibromyalgia, multiple sclerosis, neuropathies and myopathies; * patients with hypothyroidism or hyperthyreosis diagnosed clinically; * patient history and physical examination suggestive of severe hepatorenal failure; * patients with decompensated diabetes mellitus (fasting glucose above 180 mg / dl); * patients being treated for cancer; * amendment of the routine of life during the study as early vacation or suspected change in working hours; * patients with complaints of excessive sleepiness caused by organic source frameworks such as sleep apnea and morbid obesity (bmi above 35); * history of hypersensitivity to any component of the product under investigation; * any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study.

Keywords: reduction of stress and fatigue
comparing bowen therapy with ice to medical massage for acute ankle sprain

Conditions: Ankle Sprains

Summary: foot pain is particularly prevalent among older adults, affecting approximately 20% to 37% of men and women aged 45 years and older living in the community. ankle pain is somewhat less common. this study evaluates the combined impact of cryotherapy (ice application) with bowen therapy versus traditional medical massage in alleviating symptoms. a total of 41 patients, aged 32-75 years participated and were divided into two treatment groups: one receiving medical massage and ice, and the other bowen therapy and ice, with three sessions over 15 days. pain and functionality were measured using the vas pain scale and roland-morris questionnaire. findings revealed improvements in both groups, with the bowen therapy group achieving greater pain reduction and functional improvement, suggesting potential advantages of bowen therapy combined with cryotherapy for managing symptoms.


Eligibility criteria:
inclusion criteria: * participants aged 32 to 75 years. * diagnosed with ankle sprain by a qualified healthcare professional (physiatrist or orthopedist). * able to provide informed consent. * willing to comply with the study protocol and attend all scheduled therapy sessions. exclusion criteria: * presence of serious spinal pathologies (e.g., cancer, osteoporosis, trauma, or fracture). * history of significant neurological disorders or conditions affecting mobility. * pregnancy or breastfeeding. * previous surgical interventions on the spine or significant other surgeries within the last six months. * current use of medications that affect pain perception (e.g., opioids). * participation in other therapeutic interventions for low back pain during the study period.

Keywords: bowen therapy cryotherapy